Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bone resorption displays marked diurnal variation. Reversible inhibition of bone resorption may result in best possible efficacy when bone resorption peaks. The aim of the study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral salmon calcitonin (sCT) and the effect of timing of drug intake. METHODS: The study was a randomized, double-blind, double-dummy, placebo-controlled, phase I study to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral sCT in healthy postmenopausal women. Totally 81 subjects were included, aimed at investigation of a morning dose given at 8:00 (n = 42), a pre-dinner dose given at 17:00 (n = 20), and an evening dose given at 22:00 (n = 19). Plasma sCT concentrations and bone resorption (C-terminal-telopeptide of collagen type I (CTX-I)) was assessed. RESULTS: Morning and pre-dinner dosing led to comparable concentration of sCT of 45 pg/ml, whereas there was a tendency towards lower Cmax for the evening dosing having a mean of 24 pg/ml. The maximum difference from placebo was observed 1 to 3 hours post-dose with a 40 to 50% suppression consequent to morning dose, and about 75% suppression after pre-dinner and evening dose, due to the increase bone resorption as a result of circadian variation. CONCLUSION: The study suggests that orally administered 0.8 mg of salmon calcitonin was effective in suppression of serum CTX irrespective of time of dosing. The pre-dinner dosing resulted in optimum efficacy response corresponding to an overall suppression of bone resorption by 25%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood
Sørensen, M. G., Henriksen, K., Schaller, S., Henriksen, D. B., Nielsen, F. C., Dziegiel, M. H., & Karsdal, M. A. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0725-9 · Cited by 143 · cited 1×
“Binding of calcitonin to the calcitonin receptor on osteoclasts results in a reduction in a raid bone resorption [ 3- 5 ]. Salmon calcitonin is among to most potent calcitonins, and belongs to the teleost/avian family[1].”
Self-citationBagger, Y. Z., Tankó, L. B., Alexandersen, P., Karsdal, M. A., Olson, M., Mindeholm, L., Azria, M., & Christiansen, C. (2005) · Bone · doi:10.1016/j.bone.2005.04.032 · Cited by 109 · cited 2×
“Preliminary evidence suggests that calcitonin may be a potential treatment for osteoarthritis that also entails increased osteoclast function [8-10].”
Self-citationSondergaard, B., Oestergaard, S., Christiansen, C., Tankó, L. B., & Karsdal, M. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22797 · Cited by 65 · cited 2×
“Preliminary evidence suggests that calcitonin may be a potential treatment for osteoarthritis that also entails increased osteoclast function [ 8-10 ].”
Self-citation
Cited by
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
The future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 313
Self-citationKarsdal, M. A., Byrjalsen, I., Alexandersen, P., Bihlet, A., Andersen, J. R., Riis, B. J., Bay-Jensen, A. C., & Christiansen, C. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2014.12.019 · Cited by 143
Self-citationHenriksen, K., Byrjalsen, I., Andersen, J. R., Bihlet, A. R., Russo, L. A., Alexandersen, P., Valter, I., Qvist, P., Lau, E., Riis, B. J., et al. (2016) · Bone · doi:10.1016/j.bone.2016.07.019 · Cited by 78
Self-citationInsights into the role of circadian rhythms in bone metabolism: A promising intervention target?
Song, C., Wang, J., Kim, B., Lu, C., Zhang, Z., Liu, H., Kang, H., Sun, Y., Guan, H., Fang, Z., et al. (2018) · BioMed Research International · doi:10.1155/2018/9156478 · Cited by 66
“calcitonin intake at three different time points (morning, predinner and evening) in healthy postmenopausal women and found that pre-dinner dosing of oral sCT resulted in optimal efficacy of CTX-I downregulation [125].”
Background
Metadata
- Authors
- Karsdal, M., Byrjalsen, I., Riis, B., & Christiansen, C.
- Venue
- BMC Clinical Pharmacology
- Published
- 2008-12
- Volume
- 8
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1472-6904 (ISSN-L)
- OpenAlex
- W2033378858
- Cited by
- 50
- References
- 4
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. https://app.cochat.ai/papers/10.1186/1472-6904-8-12
- The paper
- Karsdal, M., Byrjalsen, I., Riis, B., & Christiansen, C. (2008). Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clinical Pharmacology. https://doi.org/10.1186/1472-6904-8-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.